Will novel agents for ALL finally change the natural history?

被引：6

作者：

Douer, Dan ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Med, Leukemia Serv, New York, NY 10065 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2014年 / 27卷 / 3-4期

关键词：

acute lymphoblastic leukemia; ALL; immunotherapy; CAR T cells; targeted agents; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; CHILDRENS CANCER GROUP; TERM-FOLLOW-UP; PEDIATRIC REGIMEN; YOUNG-ADULTS; GROUP-B; ANTIBODY BLINATUMOMAB; DOSE INTENSIFICATION; OLDER ADOLESCENTS;

D O I：

10.1016/j.beha.2014.10.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pediatric acute lymphoblastic leukemia (ALL) cure rates have markedly improved over the past years to approximately 85%, but remain at 40%-50% in adults. Redefining current adult chemotherapy regimens is likely to improve the natural course of the disease, but new agents are needed. Immunotherapy approaches for pre-B ALL are in the forefront of research on novel agents; in particular, advances are being made in manipulating autologous T cells either by infusion of a bifunctional antibody (eg, blinatumomab) or by ex vivo genetic modification of chimeric antigen receptors (CARs). The natural course of Philadelphia positive ALL has already improved by targeting ABL/BCR1. Other mutated genes are being discovered and novel small molecules that target their products are being studied in clinical trials. Finally, ALL is a heterogeneous disease and novel agents are likely to impact the natural course of smaller populations of biologically defined ALL subtypes. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：247 / 258

页数：12

共 60 条

[1]

Advani AS, 2013, BLOOD, V122, P3903

[2] Acute Lymphoblastic Leukemia [J].

Alvarnas, Joseph C. ;

Brown, Patrick A. ;

Aoun, Patricia ;

Ballen, Karen Kuhn ;

Bellam, Naresh ;

Blum, William ;

Boyer, Michael W. ;

Carraway, Hetty E. ;

Coccia, Peter F. ;

Coutre, Steven E. ;

Cultrera, Jennifer ;

Damon, Lloyd E. ;

DeAngelo, Daniel J. ;

Douer, Dan ;

Frangoul, Haydar ;

Frankfurt, Olga ;

Goorha, Salil ;

Millenson, Michael M. ;

O'Brien, Susan ;

Petersdorf, Stephen H. ;

Rao, Arati V. ;

Terezakis, Stephanie ;

Uy, Geoffrey ;

Wetzler, Meir ;

Zelenetz, Andrew D. ;

Naganuma, Maoko ;

Gregory, Kristina M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (07) :858-913

[3] DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis [J].

Anh Tram Nguyen ;

Taranova, Olena ;

He, Jin ;

Zhang, Yi .

BLOOD, 2011, 117 (25) :6912-6922

[4] Modern Therapy of Acute Lymphoblastic Leukemia [J].

Bassan, Renato ;

Hoelzer, Dieter .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :532-543

[5] CARs and cancers: questions and answers [J].

Brentjens, Renier J. .

BLOOD, 2012, 119 (17) :3872-3873

[6] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias [J].

Brentjens, Renier J. ;

Riviere, Isabelle ;

Park, Jae H. ;

Davila, Marco L. ;

Wang, Xiuyan ;

Stefanski, Jolanta ;

Taylor, Clare ;

Yeh, Raymond ;

Bartido, Shirley ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Bernal, Yvette ;

Pegram, Hollie ;

Przybylowski, Mark ;

Hollyman, Daniel ;

Usachenko, Yelena ;

Pirraglia, Domenick ;

Hosey, James ;

Santos, Elmer ;

Halton, Elizabeth ;

Maslak, Peter ;

Scheinberg, David ;

Jurcic, Joseph ;

Heaney, Mark ;

Heller, Glenn ;

Frattini, Mark ;

Sadelain, Michel .

BLOOD, 2011, 118 (18) :4817-4828

[7] Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor [J].

Daigle, Scott R. ;

Olhava, Edward J. ;

Therkelsen, Carly A. ;

Majer, Christina R. ;

Sneeringer, Christopher J. ;

Song, Jeffrey ;

Johnston, L. Danielle ;

Scott, Margaret Porter ;

Smith, Jesse J. ;

Xiao, Yonghong ;

Jin, Lei ;

Kuntz, Kevin W. ;

Chesworth, Richard ;

Moyer, Mike P. ;

Bernt, Kathrin M. ;

Tseng, Jen-Chieh ;

Kung, Andrew L. ;

Armstrong, Scott A. ;

Copeland, Robert A. ;

Richon, Victoria M. ;

Pollock, Roy M. .

CANCER CELL, 2011, 20 (01) :53-65

[8] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].

Davila, Marco L. ;

Riviere, Isabelle ;

Wang, Xiuyan ;

Bartido, Shirley ;

Park, Jae ;

Curran, Kevin ;

Chung, Stephen S. ;

Stefanski, Jolanta ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Fink, Mitsu ;

Shinglot, Himaly ;

Youssif, Maher ;

Satter, Mark ;

Wang, Yongzeng ;

Hosey, James ;

Quintanilla, Hilda ;

Halton, Elizabeth ;

Bernal, Yvette ;

Bouhassira, Diana C. G. ;

Arcila, Maria E. ;

Gonen, Mithat ;

Roboz, Gail J. ;

Maslak, Peter ;

Douer, Dan ;

Frattini, Mark G. ;

Giralt, Sergio ;

Sadelain, Michel ;

Brentjens, Renier .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[9] A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [J].

DeAngelo, Daniel J. ;

Dahlberg, Suzanne ;

Silverman, Lewis B. ;

Couban, Stephen ;

Amrein, Philip C. ;

Seftel, Matthew D. ;

Turner, A. Robert ;

Leber, Brian ;

Howsan-Jan, Kang ;

Wadleigh, Martha ;

Sirulnik, L. Andres ;

Supko, Jeffrey ;

Galinsky, Ilene ;

Sallan, Stephen E. ;

Stone, Richard M. .

BLOOD, 2007, 110 (11) :181A-181A

[10] Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 [J].

DeAngelo, Daniel J. ;

Yu, Daohai ;

Johnson, Jeffrey L. ;

Coutre, Steven E. ;

Stone, Richard M. ;

Stopeck, Alison T. ;

Gockerman, Jon P. ;

Mitchell, Beverly S. ;

Appelbaum, Frederick R. ;

Larson, Richard A. .

BLOOD, 2007, 109 (12) :5136-5142

← 1 2 3 4 5 6 →